Literature DB >> 24262438

Molecular wanderings through the DNA damage response and risk for ovarian cancer.

Michael A Bookman1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24262438     DOI: 10.1093/jnci/djt350

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  2 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

2.  PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.

Authors:  Paul D P Pharoah; Honglin Song; Ed Dicks; Maria P Intermaggio; Patricia Harrington; Caroline Baynes; Kathryn Alsop; Natalia Bogdanova; Mine S Cicek; Julie M Cunningham; Brooke L Fridley; Aleksandra Gentry-Maharaj; Peter Hillemanns; Shashi Lele; Jenny Lester; Valerie McGuire; Kirsten B Moysich; Samantha Poblete; Weiva Sieh; Lara Sucheston-Campbell; Martin Widschwendter; Alice S Whittemore; Thilo Dörk; Usha Menon; Kunle Odunsi; Ellen L Goode; Beth Y Karlan; David D Bowtell; Simon A Gayther; Susan J Ramus
Journal:  J Natl Cancer Inst       Date:  2016-01-27       Impact factor: 13.506

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.